Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter McNally

Gastroenterology Ft Carson, CO Doctor of Osteopathy

NPI 1013987965 CMS profile 273257

Evans Army Community Hospital, Gi Clinic, Ft Carson, CO 80913

Open in the dashboard

General payments

$1,102,902

628 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter McNally of Ft Carson, CO is reported in the CMS Open Payments database as having received $1,102,902 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $219,462 117
2024 General $199,354 117
2023 General $105,466 63
2022 General $186,692 92
2021 General $112,209 56
2020 General $40,801 25
2019 General $238,917 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter McNally
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Peter McNally were reported at $219,462. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Peter McNally Gastroenterology median Middle half National median
2019 $238,917 $417 $126–$1,100 $163
2020 $40,801 $224 $74–$624 $114
2021 $112,209 $352 $106–$1,054 $132
2022 $186,692 $448 $129–$1,270 $149
2023 $105,466 $533 $150–$1,390 $160
2024 $199,354 $605 $160–$1,606 $164
2025 $219,462 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $311,029 119 payments
  2. Janssen Biotech, Inc. $276,859 170 payments
  3. Pfizer Inc. $196,108 135 payments
  4. Janssen Scientific Affairs, LLC $119,617 80 payments
  5. E.R. Squibb & Sons, L.L.C. $106,168 52 payments
  6. Madrigal Pharmaceuticals $28,297 14 payments
  7. Horizon Therapeutics plc $19,225 8 payments
  8. AbbVie, Inc. $18,571 20 payments
  9. Phathom Pharmaceuticals, Inc. $13,729 12 payments
  10. Gilead Sciences, Inc. $5,649 8 payments
  11. Other $7,648 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $901,870 209 payments
  2. Travel and Lodging $159,079 335 payments
  3. Honoraria $23,680 8 payments
  4. Consulting Fee $9,048 6 payments
  5. Food and Beverage $5,821 68 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,400 1 payment
  7. Education $4 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $291,279 181 payments
  2. ENTYVIO Internal Medicine $264,458 102 payments
  3. TREMFYA $186,760 118 payments
  4. XELJANZ $116,896 82 payments
  5. ZEPOSIA $107,491 56 payments
  6. VELSIPITY $66,780 44 payments
  7. Entyvio Lower GI $46,570 17 payments
  8. REZDIFFRA $27,240 13 payments
  9. VOQUEZNA $13,729 12 payments
  10. INFLECTRA $12,432 9 payments
  11. Other $12,923 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record